SCHEMBL4959522

SCHEMBL4959522

CC(O)C(N)N1CCOCC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.37
KCNA5 P22460 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
PKM P14618 1/20 0.34
ALDH1A1 P00352 5/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 2/20 0.34
MAPT P10636 2/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
ANPEP P15144 1/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
CYP2C19 P33261 1/20 0.33
HSD17B10 Q99714 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7064817 1.00 USP2 (0.37) USP2KCNA5SMN1; SMN2PKMALDH1A1
SCHEMBL6439179 1.00 USP2 (0.37) USP2KCNA5SMN1; SMN2PKMALDH1A1
SCHEMBL2313171 0.81 KCNA5 (0.37) USP2KCNA5SMN1; SMN2PKMALDH1A1
SCHEMBL10705475 0.77 USP2 (0.37) USP2KCNA5SMN1; SMN2PKMALDH1A1
SCHEMBL22123274 0.77 USP2 (0.37) USP2KCNA5SMN1; SMN2PKMALDH1A1
SCHEMBL3719290 0.76 DPP7 (0.36) SMN1; SMN2KMT2A
SCHEMBL4359607 0.76 USP2 (0.39) USP2KCNA5SMN1; SMN2PKMALDH1A1
SCHEMBL39895 0.75
SCHEMBL134990 0.75
SCHEMBL6384685 0.74 USP2 (0.38) USP2KCNA5SMN1; SMN2PKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562600-A4 COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS SUGEN INC (US) 2008-06-25 EP disclosed
EP-1446117-A4 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS SUGEN INC (US) 2008-01-23 EP disclosed
EP-1749002-A1 PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY F.HOFFMANN-LA ROCHE AG (CH) 2007-02-07 EP disclosed
EP-1599207-A2 TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS Sugen, Inc. (US) 2005-11-30 EP disclosed
WO-2005108393-A1 PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2005-11-17 WO disclosed
EP-1562600-A2 COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS Sugen, Inc. (US) 2005-08-17 EP disclosed
EP-1476443-A2 PROCESS FOR PREPARING INDOLINONE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2004-11-17 EP disclosed
WO-2004075775-A2 TREATMENT OF EXCESSIVE OSTEOLYISIS WITH INDOLINONE COMPOUNDS SUGEN, INC. (US) 2004-09-10 WO disclosed
EP-1446117-A2 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS Sugen, Inc. (US) 2004-08-18 EP disclosed
WO-2004045523-A2 COMBINATION ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR CELL PROLIFERATION DISORDERS SUGEN, INC. (US) 2004-06-03 WO disclosed
EP-1370554-A1 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2003-12-17 EP disclosed
WO-2003070725-A2 PROCESS FOR PREPARING INDOLINONE DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 2003-08-28 WO disclosed
WO-2003035009-A2 TREATMENT OF ACUTE MYELOID LEUKEMIA WITH INDOLINONE COMPOUNDS SUGEN, INC. (US) 2003-05-01 WO disclosed
WO-2002081466-A1 PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES SUGEN, INC. (US) 2002-10-17 WO disclosed
WO-2002066463-A1 3-(4-AMIDOPYRROL-2-YLMETHLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS PHARMACIA & UPJOHN COMPANY (US) 2002-08-29 WO disclosed